Expert reviews real-world data on BCG retreatment after failure in non-muscle-invasive bladder cancer
Dr Joshua J. Meeks, MD, PhD, provided an overview of a real-world study that examined the use of BCG retreatment in patients with non‑muscle‑invasive bladder cancer (NMIBC) who had previously failed standard BCG therapy.
The study focused on outcomes such as disease recurrence, progression, and safety of a second BCG course, although specific results were not detailed in the source material.
Meeks highlighted the clinical relevance of retreatment strategies, noting that many clinicians face decisions about how to manage BCG‑refractory NMIBC and that real‑world evidence can inform practice.
He also emphasized the need for further prospective data to better define the efficacy and optimal patient selection for BCG retreatment.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Dr Meeks on a Real-World Study of BCG Retreatment After BCG Failure in NMIBC”
read at onclive ↗
comments(0)
5-min edit window · permanent after that